vs

Side-by-side financial comparison of American Express (AXP) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $18.9M, roughly 25.8× American Express). American Express runs the higher net margin — 15.7% vs -10.1%, a 25.8% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 11.4%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -95.6%).

American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

AXP vs CLOV — Head-to-Head

Bigger by revenue
CLOV
CLOV
25.8× larger
CLOV
$487.7M
$18.9M
AXP
Growing faster (revenue YoY)
CLOV
CLOV
+33.3% gap
CLOV
44.7%
11.4%
AXP
Higher net margin
AXP
AXP
25.8% more per $
AXP
15.7%
-10.1%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-95.6%
AXP

Income Statement — Q1 2026 vs Q4 2025

Metric
AXP
AXP
CLOV
CLOV
Revenue
$18.9M
$487.7M
Net Profit
$3.0M
$-49.3M
Gross Margin
Operating Margin
-10.1%
Net Margin
15.7%
-10.1%
Revenue YoY
11.4%
44.7%
Net Profit YoY
15.0%
-123.2%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXP
AXP
CLOV
CLOV
Q1 26
$18.9M
Q4 25
$10.9B
$487.7M
Q3 25
$10.4B
$496.6M
Q2 25
$10.3B
$477.6M
Q1 25
$9.6B
$462.3M
Q4 24
$10.0B
$337.0M
Q3 24
$9.7B
$331.0M
Q2 24
$9.8B
$356.3M
Net Profit
AXP
AXP
CLOV
CLOV
Q1 26
$3.0M
Q4 25
$2.5B
$-49.3M
Q3 25
$2.9B
$-24.4M
Q2 25
$2.9B
$-10.6M
Q1 25
$2.6B
$-1.3M
Q4 24
$2.2B
$-22.1M
Q3 24
$2.5B
$-9.2M
Q2 24
$3.0B
$7.4M
Gross Margin
AXP
AXP
CLOV
CLOV
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Operating Margin
AXP
AXP
CLOV
CLOV
Q1 26
Q4 25
28.2%
-10.1%
Q3 25
36.7%
-4.9%
Q2 25
34.4%
-2.2%
Q1 25
34.6%
-0.3%
Q4 24
27.7%
-6.4%
Q3 24
33.0%
-2.7%
Q2 24
38.6%
2.0%
Net Margin
AXP
AXP
CLOV
CLOV
Q1 26
15.7%
Q4 25
22.5%
-10.1%
Q3 25
27.9%
-4.9%
Q2 25
28.0%
-2.2%
Q1 25
26.8%
-0.3%
Q4 24
21.8%
-6.6%
Q3 24
25.8%
-2.8%
Q2 24
30.7%
2.1%
EPS (diluted)
AXP
AXP
CLOV
CLOV
Q1 26
Q4 25
$3.52
Q3 25
$4.14
Q2 25
$4.08
Q1 25
$3.64
Q4 24
$3.04
Q3 24
$3.49
Q2 24
$4.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXP
AXP
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$78.3M
Total DebtLower is stronger
$60.4M
Stockholders' EquityBook value
$34.0M
$308.7M
Total Assets
$308.9M
$541.0M
Debt / EquityLower = less leverage
1.78×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXP
AXP
CLOV
CLOV
Q1 26
Q4 25
$742.0M
$78.3M
Q3 25
$1.3B
Q2 25
$197.0M
Q1 25
$261.0M
Q4 24
$221.0M
$194.5M
Q3 24
$120.0M
$288.0M
Q2 24
$188.0M
$254.8M
Total Debt
AXP
AXP
CLOV
CLOV
Q1 26
$60.4M
Q4 25
$56.4B
Q3 25
$57.8B
Q2 25
$58.2B
Q1 25
$51.2B
Q4 24
$49.7B
Q3 24
$53.5B
Q2 24
$51.5B
Stockholders' Equity
AXP
AXP
CLOV
CLOV
Q1 26
$34.0M
Q4 25
$33.5B
$308.7M
Q3 25
$32.4B
$340.9M
Q2 25
$32.3B
$344.2M
Q1 25
$31.2B
$336.1M
Q4 24
$30.3B
$341.1M
Q3 24
$29.7B
$342.2M
Q2 24
$29.5B
$324.9M
Total Assets
AXP
AXP
CLOV
CLOV
Q1 26
$308.9M
Q4 25
$300.1B
$541.0M
Q3 25
$297.6B
$559.7M
Q2 25
$295.6B
$575.0M
Q1 25
$282.2B
$583.7M
Q4 24
$271.5B
$580.7M
Q3 24
$271.0B
$653.0M
Q2 24
$272.2B
$674.2M
Debt / Equity
AXP
AXP
CLOV
CLOV
Q1 26
1.78×
Q4 25
1.68×
Q3 25
1.78×
Q2 25
1.80×
Q1 25
1.64×
Q4 24
1.64×
Q3 24
1.80×
Q2 24
1.74×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXP
AXP
CLOV
CLOV
Operating Cash FlowLast quarter
$-68.2M
Free Cash FlowOCF − Capex
$-68.7M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXP
AXP
CLOV
CLOV
Q1 26
Q4 25
$3.1B
$-68.2M
Q3 25
$6.2B
$12.1M
Q2 25
$4.4B
$5.4M
Q1 25
$4.8B
$-16.3M
Q4 24
$5.8B
$-85.8M
Q3 24
$-1.8B
$50.0M
Q2 24
$4.5B
$44.8M
Free Cash Flow
AXP
AXP
CLOV
CLOV
Q1 26
Q4 25
$2.3B
$-68.7M
Q3 25
$5.6B
$11.4M
Q2 25
$3.7B
$4.8M
Q1 25
$4.3B
$-16.5M
Q4 24
$5.3B
$-86.1M
Q3 24
$-2.3B
$49.6M
Q2 24
$4.0B
$44.4M
FCF Margin
AXP
AXP
CLOV
CLOV
Q1 26
Q4 25
21.4%
-14.1%
Q3 25
53.6%
2.3%
Q2 25
36.3%
1.0%
Q1 25
45.0%
-3.6%
Q4 24
53.1%
-25.6%
Q3 24
-23.3%
15.0%
Q2 24
40.4%
12.5%
Capex Intensity
AXP
AXP
CLOV
CLOV
Q1 26
Q4 25
6.6%
0.1%
Q3 25
6.3%
0.1%
Q2 25
6.0%
0.1%
Q1 25
4.5%
0.0%
Q4 24
5.0%
0.1%
Q3 24
4.7%
0.1%
Q2 24
5.8%
0.1%
Cash Conversion
AXP
AXP
CLOV
CLOV
Q1 26
Q4 25
1.25×
Q3 25
2.15×
Q2 25
1.51×
Q1 25
1.84×
Q4 24
2.66×
Q3 24
-0.72×
Q2 24
1.50×
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXP
AXP

Discount revenue$9.5M50%
Other$8.9M47%
Deposits with banks and other$512.0K3%

CLOV
CLOV

Segment breakdown not available.

Related Comparisons